Publications

• Pérez A, González-Manzano S, Jimenez R, Perez-Abud R, Haro JM, Osuna A, Santos-Buelga C, Duarte J, Perez-Vizcaino F. The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity. Pharmacol. Res. 2014 Nov; 89: 11-8

  IF: 4.408, Quartile: 1

  View abstract

• Duarte J, Francisco V, Perez-Vizcaino F. Modulation of nitric oxide by flavonoids. Food Funct 2014 Aug; 5(8): 1653-68

  IF: 2.907, Quartile: 1

  View abstract

• Cervera C, Castañeda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericàs JM, Falces C, Armero Y, Almela M, Ninot S, Paré JC, Mestres CA, Gatell JM, Marco F, Miró JM. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin. Infect. Dis. 2014 Jun; 58(12): 1668-75

  IF: 9.416, Quartile: 1, Decile: 1

  View abstract

• Andreu D, Ortiz-Pérez JT, Boussy T, Fernández-Armenta J, de Caralt TM, Perea RJ, Prat-González S, Mont L, Brugada J, Berruezo A. Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. Eur. Heart J. 2014 May; 35(20): 1316-26

  IF: 14.723, Quartile: 1, Decile: 1

  View abstract

• Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernández JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ 2014; 349: g6427

  IF: 16.378, Quartile: 1, Decile: 1

  View abstract

• Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gómez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 2015 Jan; 8(1): 189-97

  IF: 7.44, Quartile: 1, Decile: 1

  View abstract

• Ribera A, Slof J, Andrea R, Falces C, Gutiérrez E, Del Valle-Fernández R, Morís-de la Tassa C, Mota P, Oteo JF, Cascant P, Altisent OA, Sureda C, Serra V, García-Del Blanco B, Tornos P, García-Dorado D, Ferreira-González I. Transfemoral transcatheter aortic valve replacement compared with surgical replacement in patients with severe aortic stenosis and comparable risk: cost-utility and its determinants. Int. J. Cardiol. 2015 Mar; 182: 321-8

  IF: 6.175, Quartile: 1, Decile: 1

  View abstract

• Avanzas P, Arias MÁ, Ferreira I, Perez de Isla L, Sanchis J. Summary of the clinical studies reported in the annual scientific sessions of the american college of cardiology (san diego, United States, march 14-16, 2015). Rev Esp Cardiol (Engl Ed) 2015 Jun; 68(6): 513.e1-8

  IF: 3.342, Quartile: 2

  View abstract

• Cequier A. Comments on the 2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) 2015 Feb; 68(2): 92-7

  IF: 3.342, Quartile: 3

  View abstract

• Cuadrado-Godia E. Early neurological deterioration, easy methods to detect it. Indian J. Med. Res. 2015 Mar; 141(3): 266-8

  IF: 1.661, Quartile: 2

  View abstract

• Escudero P, Martinez de Marañón A, Collado A, Gonzalez-Navarro H, Hermenegildo C, Peiró C, Piqueras L, Sanz MJ. Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARα and RXR/PPARγ interactions. Antioxid. Redox Signal. 2015 Apr; 22(11): 901-20

  IF: 7.667, Quartile: 1, Decile: 1

  View abstract

• Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015 Jan; 385(9965): 331-40

  IF: 39.207, Quartile: 1, Decile: 1

  View abstract

• Ledesma M, Hurtado-Roca Y, León M, Giraldo P, Pocoví M, Civeira F, Guallar E, Ordovas JM, Casasnovas JA, Laclaustra M. Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon Workers' Health Study (AWHS). J. Clin. Endocrinol. Metab. 2015 May; 100(5): 2081-9

  IF: 6.31, Quartile: 1

  View abstract

• Ascaso JF, Mata P, Arbona C, Civeira F, Valdivielso P, Masana L. [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)]. Clin Investig Arterioscler 2015; 27(2): 80-96

  IF: 0

  View abstract

• Guardiola M, Cofán M, De Castro-Orós I, Cenarro A, Plana N, Talmud PJ, Masana L, Ros E, Civeira F, Ribalta J. APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis 2015 May; 240(1): 98-104

  IF: 3.971, Quartile: 1

  View abstract